NASDAQ$VERU
Veru Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Net revenues increased by 43% and gross profit rose by 61%.
Veru Inc. reported a strong fiscal 2020 second quarter with net revenues increasing by 43% and gross profit up by 61%. The growth was primarily driven by substantial growth in prescription sales of FC2. The company also made significant clinical progress in advanced prostate cancer with VERU-111 and initiated a Phase 2 clinical study for VERU-111 as a potential treatment for COVID-19.
- Net revenues increased 43% to $9.9 million from $7.0 million.
- Gross profit increased 61% to $7.4 million from $4.6 million.
- Gross margin climbed to 75% of net revenues from 66%.
- FC2 US prescription net revenues grew 168% to $7.0 million from $2.6 million.
Headline financials
Revenue & EPS history
Veru · Revenue · Quarterly
$9.94M
Forward guidance
Veru is focused in prostate cancer and oncology, and will pursue COVID-19 indication with VERU-111, due to the urgency of the current global pandemic.
Tailwinds
- Initiated Phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19.
- Expect the first patient to be dosed within 2 weeks for COVID-19 trial.
- VERU-111 has the potential to treat both SARS-CoV-2 infection and the associated reactive severe lung inflammation in COVID-19 patients at high risk for ARDS.
- Applied for significant grant funding through both BARDA and DARPA to expedite the clinical development program of VERU-111 for COVID-19.
- Plan to advance Zuclomiphene Citrate to a Phase 3 clinical trial in men with advanced prostate cancer who experience moderate to severe hot flashes with a potential start date in late calendar year 2020.
Headwinds
- There can be no assurances that any grant funding for VERU-111 COVID-19 will be provided.
- VERU-100 is anticipated to enter a Phase 2 dose-finding study with a potential start date in the third quarter of calendar year 2020.
- The expected submission of the NDA for TADFIN is the fourth quarter of calendar year 2020 or early 2021.
- The Company may be unable to develop a drug that successfully treats the COVID-19 virus in a timely manner, if at all.
- Pursuit of a COVID-19 treatment candidate may cause delays in or otherwise negatively impact other development programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2020
+1.5%
Avg return
Earnings day
+8.3%
Avg return
5 days after
+9.6%
Avg return
30 days after
45%
30 / 66 earnings
Positive
+83.7%
Q4 2020
Best reaction
-23.5%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.8% | -6.7% | +33.8% | |
| Q1 2026 | -0.4% | -0.9% | +3.5% | |
| Q4 2025 | -8.4% | -6.1% | +10.2% | |
| Q3 2025 | -12.0% | +0.0% | -0.8% | |
| Q2 2025 | +4.1% | +4.0% | +24.0% | |
| Q1 2025 | -4.5% | +0.0% | -12.7% | |
| Q4 2024 | -1.3% | -9.7% | +2.8% | |
| Q3 2024 | +7.1% | +6.5% | +10.4% | |
| Q4 2023 | +3.5% | +11.8% | -4.7% | |
| Q2 2024 | -16.0% | -18.4% | -43.6% | |
| Q1 2024 | -13.7% | -13.6% | +47.7% | |
| Q3 2023 | +5.6% | +3.7% | -4.6% | |
| Q2 2023 | -23.5% | -27.5% | -12.1% | |
| Q1 2023 | -19.1% | -21.8% | -57.5% | |
| Q4 2022 | +2.9% | -0.5% | -1.3% | |
| Q3 2022 | +62.1% | +89.0% | +32.3% | |
| Q2 2022 | +59.3% | +91.2% | +60.8% | |
| Q1 2022 | +9.4% | +7.4% | -8.8% | |
| Q4 2021 | -12.3% | -8.1% | -14.8% | |
| Q3 2021 | +8.8% | -2.0% | +31.3% | |
| Q2 2021 | -3.2% | +3.7% | +18.7% | |
| Q1 2021 | -2.3% | +7.8% | -22.3% | |
| Q4 2020 | +83.7% | +198.5% | +193.8% | |
| Q3 2020 | -11.6% | -10.9% | -9.9% | |
| Q2 2020 | +13.9% | +10.5% | -5.4% | |
| Q1 2020 | +0.9% | -0.9% | -29.8% | |
| Q4 2019 | -1.6% | +17.1% | +64.5% | |
| Q3 2019 | -14.0% | -11.0% | -16.2% | |
| Q2 2019 | -4.8% | -1.8% | +20.8% | |
| Q1 2019 | -8.1% | -10.7% | +0.0% | |
| Q4 2018 | -4.9% | +0.7% | -1.4% | |
| Q3 2018 | +1.0% | +1.0% | -13.6% | |
| Q2 2018 | -1.2% | +6.6% | +18.7% | |
| Q1 2018 | +0.8% | +2.3% | +50.4% | |
| Q4 2017 | +28.9% | +29.8% | +10.5% | |
| Q3 2017 | -11.3% | -4.0% | +2.0% | |
| Q2 2017 | -1.0% | -2.9% | +17.6% | |
| Q1 2017 | +1.9% | +3.8% | -1.9% | |
| Q4 2016 | -6.2% | -8.8% | -10.6% | |
| Q3 2016 | -2.3% | +1.6% | +2.3% | |
| Q2 2016 | -12.3% | — | — | |
| Q1 2016 | +10.2% | — | — | |
| Q4 2015 | +0.6% | — | — | |
| Q3 2015 | +9.9% | — | — | |
| Q2 2015 | -8.1% | — | — | |
| Q1 2015 | +2.9% | — | — | |
| Q4 2014 | -8.5% | — | — | |
| Q3 2014 | -5.8% | — | — | |
| Q2 2014 | -3.7% | — | — | |
| Q1 2014 | -4.1% | — | — | |
| Q4 2013 | +3.4% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q2 2013 | +5.8% | — | — | |
| Q1 2013 | -4.2% | — | — | |
| Q4 2012 | -0.7% | — | — | |
| Q3 2012 | +4.7% | — | — | |
| Q2 2012 | -9.2% | — | — | |
| Q1 2011 | +1.5% | — | — | |
| Q1 2012 | +4.7% | — | — | |
| Q4 2009 | +5.5% | — | — | |
| Q4 2011 | +5.5% | — | — | |
| Q2 2011 | +5.5% | — | — | |
| Q4 2010 | -5.4% | — | — | |
| Q3 2010 | -5.4% | — | — | |
| Q3 2011 | -5.4% | — | — | |
| Q2 2010 | +0.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro